MLANA and melanoma: We propose that non-cutaneous melanoma, with a low tumor mutational burden, low neo-antigen load, or those that express higher levels of melanoma-associated antigens (gp100, MART1, tyrosinase, and TRP-1) would be intratumoral homogenous, rendering these tumors susceptible to elimination of antigen-specific CAR T cells (recognizes one antigen) (Figure 4B and Figure 6).